Pfizer (NYSE: PFE) SVP discloses stock and appreciation right holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
PFIZER INC Senior Vice President Dennis P. Hancock filed an initial ownership report showing direct holdings of common stock and stock appreciation rights (SARs). The filing lists 45,097 shares of Pfizer common stock held directly as of the reporting date.
Hancock also holds multiple SAR awards tied to Pfizer common stock, including 33,051 underlying shares at an exercise price of $25.75 expiring on March 4, 2030, and 15,748 underlying shares at $26.58 expiring on March 3, 2031. Additional SAR series range from $26.89 to $45.96 per share, with expirations between 2027 and 2031. According to the footnotes, these SARs are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth or seventh anniversary of the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
Hancock Dennis P
Role
Senior Vice President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Appreciation Rights — 33,051 shares (Direct);
Common Stock — 45,097 shares (Direct)
Footnotes (1)
- The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.
Key Figures
Direct common stock holdings: 45,097 shares
SAR block at $25.75: 33,051 underlying shares
SAR block at $26.58: 15,748 underlying shares
+4 more
7 metrics
Direct common stock holdings
45,097 shares
Total Pfizer common stock held directly following reported holdings
SAR block at $25.75
33,051 underlying shares
Stock Appreciation Rights, exercise price $25.75, expire March 4, 2030
SAR block at $26.58
15,748 underlying shares
Stock Appreciation Rights, exercise price $26.58, expire March 3, 2031
SAR block at $26.89 (2029)
13,430 underlying shares
Stock Appreciation Rights, exercise price $26.89, expire February 27, 2029
SAR block at $26.89 (2031)
11,867 underlying shares
Stock Appreciation Rights, exercise price $26.89, expire February 27, 2031
Lowest SAR expiration
February 27, 2027
Expiration date for SARs with 9,603 underlying shares at $31.31
Highest SAR exercise price
$45.96 per share
Exercise price for SAR blocks with 6,040 and 6,868 underlying shares
Key Terms
Stock Appreciation Rights, vesting requirements, underlying security, exercise price, +2 more
6 terms
Stock Appreciation Rights financial
"security_title: Stock Appreciation Rights; underlying Pfizer common stock"
Stock appreciation rights (SARs) are a form of employee compensation that give the holder the right to receive the increase in a company's stock price over a set baseline, paid in cash or shares, without having to buy the stock. For investors, SARs matter because they can create future cash outflows or share dilution and signal how a company rewards and motivates executives — similar to giving a bonus tied directly to how well the company’s stock performs.
vesting requirements financial
"The stock appreciation rights, which are subject to certain vesting requirements, will be settled"
underlying security financial
"underlying_security_title: Common Stock; underlying_security_shares listed for each SAR grant"
exercise price financial
"conversion_or_exercise_price fields such as 25.7500 and 45.9600 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date fields including 2027-02-27 and 2031-03-03 for SAR awards"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What does the Pfizer (PFE) Form 3 filing by Dennis P. Hancock show?
The Form 3 shows that Senior Vice President Dennis P. Hancock directly holds 45,097 Pfizer common shares and multiple stock appreciation rights (SARs). These SARs reference tens of thousands of underlying shares at fixed exercise prices and specified expiration dates between 2027 and 2031.
What stock appreciation rights are disclosed for Dennis P. Hancock at Pfizer (PFE)?
The filing lists several stock appreciation rights tied to Pfizer common stock, including blocks with 33,051, 15,748, 13,430, 11,867, 9,603, 9,102, 7,493, 8,610, 6,040 and 6,868 underlying shares. Each block has its own exercise price, expiration date and is held directly.
At what exercise prices are Dennis P. Hancock’s Pfizer (PFE) stock appreciation rights set?
The disclosed stock appreciation rights have exercise prices of $25.75, $26.58, $26.89, $31.31, $33.82, $42.30 and $45.96 per share. Each price level corresponds to separate SAR grants, all referencing Pfizer common stock as the underlying security.
When do Dennis P. Hancock’s Pfizer (PFE) stock appreciation rights expire?
The SARs expire on various dates between 2027 and 2031, including February 27, 2027, February 25, 2028, February 24 and 27, 2029, February 23 and March 4, 2030, and February 27 and March 3, 2031. Each grant lists a specific expiration date.
How will Dennis P. Hancock’s Pfizer (PFE) stock appreciation rights be settled?
According to the footnotes, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock. Settlement occurs on either the fifth or the seventh anniversary of the applicable grant date, depending on the specific SAR award.